|
December
Monday, Dec 22, 2008 Genentech Announces January 15 Webcast of Financial and Other Business Results Thursday, Dec 18, 2008 Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA) Saturday, Dec 06, 2008 Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer November Sunday, Nov 23, 2008 Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer Monday, Nov 17, 2008 Genentech Issues Dear Healthcare Provider Letter Regarding a 2nd Case of PML in a Raptiva Patient Thursday, Nov 06, 2008 Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer Monday, Nov 03, 2008 Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer October Monday, Oct 27, 2008 Rituxan Data in Patients With Rheumatoid Arthritis To Be Presented at The American College of Rheumatology Annual Scientific Meeting Sunday, Oct 19, 2008 Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue Tuesday, Oct 14, 2008 Genentech Announces Third Quarter 2008 Results See the Archives 
 |
